Journal of Gastroenterology

, Volume 44, Issue 7, pp 685–690 | Cite as

Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer

  • Takako Eguchi Nakajima
  • Yasuhide YamadaEmail author
  • Tetsutaro Hamano
  • Koh Furuta
  • Takuji Gotoda
  • Hitoshi Katai
  • Ken Kato
  • Tetsuya Hamaguchi
  • Yasuhiro Shimada
Original Article—Alimentary Tract



Adipocytokines are adipocyte-secreted hormones associated with some malignancies. We investigated the association of adipocytokines with gastric cancer.


The levels of body mass index (BMI) and adiponectin, leptin, resistin, visfatin, and C-peptide in blood at diagnosis were measured in 156 gastric cancer patients and 156 age- and sex-matched controls. Logistic regression models were used to estimate odds ratio, and one-way analysis of variance was performed to examine the prevalence of each variable between 2 or more groups.


Adiponectin, C-peptide and BMI levels were significantly lower, and resistin and visfatin levels were significantly higher in the patients on multivariate analysis (P = 0.0004, 0.0006, 0.0051, 0.0006 and 0.0013, respectively). In the controls, the inverse correlation between BMI and adiponectin was comparatively strong, but was weak in the patients. The correlation between BMI and leptin was strong in both the controls and the patients. The correlation between BMI and resistin or visfatin was not clear in either the patients or the controls. The correlation between BMI and C-peptide was not clear in the controls, but might be weak in the patients. Leptin, C-peptide and BMI levels gradually decreased with stage progression, and resistin and visfatin levels gradually increased with stage progression (P < 0.0001 for all). Comparison between 38 patients with Stage I gastric cancer and the controls showed that adiponectin level tended to decrease in the patients (P = 0.0582), and BMI level was not different between two groups (P = 0.2480).


Resistin and visfatin may be good biomarkers of gastric cancer.


Adiponectin Leptin Resistin Visfatin Gastric cancer 


  1. 1.
    Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004;23:6365–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Wolk A, Gridley G, Svensson M, McLaughlin JK, Fraumeni JF, Adam HO. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12:13–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001;92:720–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11:466–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Pannacciulli N, Vettor R, Milan G, Granzotto M, Catucci A, Federspil G, et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab. 2003;88:1748–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Wolfe BE, Jimerson DC, Orlova C, Mantzoros CS. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf). 2004;61:332–8.CrossRefGoogle Scholar
  7. 7.
    Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106:966–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Kerem M, Ferahkose Z, Yilmaz UT, Pasaoglu H, Ofluoglu E, Bedirli A, et al. Adipokines and ghrelin in gastric cancer cachexia. World J Gastroenterol. 2008;14:3633–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Jamieson NB, Brown DJ, Michael Wallace A, McMillan DC. Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine. 2004;27:90–2.PubMedCrossRefGoogle Scholar
  10. 10.
    Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Dalamaga M, Karmaniolas K, Nikolaidou A, Chamberland J, Hsi A, Dionyssiou-Asteriou A, et al. Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer. 2008;44:1744–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Ishikawa M, Kitayama J, Yamauchi T, Kadowaki T, Maki T, Miyato H, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci. 2007;98:1120–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004;27:2450–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study. Cancer Causes Control 2008.Google Scholar
  17. 17.
    Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett. 1999;463:77–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131:3109S–20S.PubMedGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Takako Eguchi Nakajima
    • 1
  • Yasuhide Yamada
    • 1
    Email author
  • Tetsutaro Hamano
    • 2
  • Koh Furuta
    • 3
  • Takuji Gotoda
    • 4
  • Hitoshi Katai
    • 5
  • Ken Kato
    • 1
  • Tetsuya Hamaguchi
    • 1
  • Yasuhiro Shimada
    • 1
  1. 1.Gastrointestinal Oncology DivisionNational Cancer Center HospitalTokyoJapan
  2. 2.Hamano Statistical Analysis Ltd.TokyoJapan
  3. 3.Clinical Laboratory DivisionNational Cancer Center HospitalTokyoJapan
  4. 4.Endoscopy DivisionNational Cancer Center HospitalTokyoJapan
  5. 5.Gastric Surgery DivisionNational Cancer Center HospitalTokyoJapan

Personalised recommendations